New drug applications approved by US FDA as of 1 - 15 November 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The minimal clinically important difference (MCID) of the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) for Asian breast cancer patients ranges from 4.50 to 10.79 points, a recent study from Singapore reveals.
A comprehensive Mendelian randomization study reveals little evidence for a linear causal relationship between circulating vitamin D concentrations and risk of colorectal, breast, prostate, ovarian, lung, and pancreatic and neuroblastoma cancer, but the existence of causal clinically relevant effects of low magnitude cannot be dismissed.
Higher fibre intake from cereals, vegetables and whole grain after the diagnosis of nonmetastatic colorectral cancer (CRC) is associated with lower CRC-specific and overall mortality, as shown in a recent study.
Aggressive dose de-escalation of radiotherapy provides similar efficacy and superior safety profile in patients with human papilloma virus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC), according to a recent study presented at the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Hypofractionated radiotherapy (HFRT) is equally effective and safe compared with conventional fractionated RT (CFRT) in Chinese breast cancer patients who have undergone mastectomy, according to a phase III study presented at the American Society for Radiation Oncology (ASTRO) 2017 Annual Meeting. [ASTRO 2017, abstract 5]
A rare copy number variant region (CNVR) at chromosome 14q11, encompassing the CHD8 gene for chromatin modification, is associated with sporadic colorectal cancer (CRC) risk such that the loss of copy number affects the expression of genes involved in CRC tumourigenesis, a recent Singapore study has shown.
Patients who underwent intrafascial nerve-sparing radical prostatectomy (NSRP) had better functional (ie, urinary continence and erectile function) and oncologic outcomes (ie, cancer control) compared with those who had interfascial NSRP, according to a meta-analysis.
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).
At the launch of Caris Molecular Intelligence® in Malaysia, Dr Andrew Dean, Head of Oncology at the St John of God Subianco Hospital, Perth, shared with the audience on molecular profiling and its benefits, with a focus on the Caris Molecular Intelligence® service.